Consistent with our results, they found the use of ER-β protein expression levels as a biomarker in tumor screening, in addition to protein expression levels of ER-α, to be a more successful indication of therapeutic responses and course/outcome of the disease in ER-positive tumors [53]. Here, ESR2 is linked to neoplasm.